Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:11 14/06/2024 BST			5-day change	1st Jan Change
27.06 ^EUR	-1.02%		-3.65%	-19.52%

06-14	Restrictions on glyphosate remain in place	DP
06-13	Archer-Daniels-Midland, Bayer to Expand Regenerative Agriculture Program to Eastern Europe	MT

Jixing Pharmaceutical Technology Co., Ltd. announced that it has received $162 million in funding from Bayer Aktiengesellschaft, RTW Investments, LP

January 05, 2024

Jixing Pharmaceutical Technology (Shanghai) Co., Ltd. announced that it has raised $162 million in a round of funding co-led by new investors Bayer Aktiengesellschaft and RTW Investments, LP on January 6, 2024. Bayer Aktiengesellschaft invested $35 million and RTW Investments, LP invested $127 million in the transaction.

Latest news about Bayer AG

Restrictions on glyphosate remain in place	06-14	DP
Archer-Daniels-Midland, Bayer to Expand Regenerative Agriculture Program to Eastern Europe	06-13	MT
Dpa-AFX Overview: COMPANIES as of 11/06/2024 - 15:15	06-11	DP
Bayer: decision in China for lung cancer	06-11	CF
Bayer's Lung Cancer Drug Gets Breakthrough Therapy Status in China	06-11	DJ
Bayer: working with PAPACKS on sustainable packaging	06-06	CF
BAYER AG : DZ Bank maintains a Buy rating	06-06	ZD
WDH/Correction/Bayer must pay significantly less in glyphosate case	06-06	DP
Bayer must pay significantly less in glyphosate case	06-06	DP
Global markets live: Inditex, Intel, TSMC, Dollar Tree, AbbVie...	06-05
Trending : Bayer-Owned Monsanto's Roundup Case Payment Cut to $400 Million	06-05	DJ
Dpa-AFX Overview: COMPANIES from 05.06.2024 - 15:15	06-05	DP
Collective bargaining partners in the chemical industry adjourn again	06-05	DP
Goldman rates Bayer at 'Neutral' - Target 31 euros	06-05	DP
Reduced penalty for Bayer inspires investors only briefly	06-05	DP
BAYER AG : Goldman Sachs remains Neutral	06-05	ZD
Interest rate hopes cause Dax to rise again	06-05	RE
Reduced fine drives Bayer - but only slight relief	06-05	DP
US Judge Lowers Bayer's Payment for Guilty Verdict in Cancer Case Linked to Roundup Weedkiller	06-05	MT
Judge cuts Bayer $2.25 billion Roundup verdict to $400 million	06-04	RE
Monsanto's Weedkiller Payout Slashed to $400 Million From $2.25 Billion	06-04	DJ
Bayer: strategic collaboration with Samsung for SDM	06-04	CF
German Shares Edge Up as Eurozone Sentiment Data Improves	05-30	MT
Burning Rock Biotech to Work With Bayer to Increase Patient Access to Precision Cancer Medicines in China	05-30	MT
Bayer Wins US FDA's Regenerative Medicine Advanced Therapy Tag for Parkinson's Disease Drug	05-30	MT

Chart Bayer AG

Duration

Period

More charts

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release

Related indices

Euro STOXX 50 Index , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : As soft as anticipated

May 14, 2024 at 07:12 pm

Bayer AG: Not out of the woods yet

March 06, 2024 at 03:46 pm

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

27.06 EUR

Average target price

36.18 EUR

Spread / Average Target

+33.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-19.52%	28.44B
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Jixing Pharmaceutical Technology Co., Ltd. announced that it has received $162 million in funding from Bayer Aktiengesellschaft, RTW Investments, LP

EPS Revisions